Groundbreaking Study of Accelerated Deep TMS
BrainsWay Ltd. (NASDAQ: BWAY), recognized worldwide for its innovative neurostimulation treatments, has made significant strides in mental health care. The preliminary findings of a multicenter, randomized controlled trial titled “Accelerated Deep TMS for Depression: Results from a Multisite, Randomized Non-Inferiority Trial” have recently garnered attention. These findings highlight the effectiveness of an advanced treatment for patients suffering from major depressive disorder (MDD).
This clinical trial stands out as the largest and most comprehensive multicenter trial focusing on the accelerated Deep Transcranial Magnetic Stimulation (Deep TMS™). Encompassing 104 adult participants, the research aimed to compare the conventional Deep TMS approach to the new, expedited treatment regimen.
Key Insights from the Clinical Trial
Patients were divided into two groups: one receiving traditional Deep TMS therapy, while the other group engaged in the accelerated approach. The accelerated protocol involved five sessions of treatment per day across six days, followed by eight continued treatment sessions within the next four weeks.
Efficacy and Results
A primary focus of the trial was the change in depressive symptoms, measured using the HDRS-21 scale. Patients who underwent accelerated treatment reported significant improvements akin to those in the standard treatment group. Specifically, HDRS scores were reduced by 18.9 points in the accelerated group, compared to 19.9 points for the standard approach.
Furthermore, the response and remission rates were remarkably similar: 87.8% and 78.0% for the accelerated TMS group, in comparison to 87.5% for both metrics in the standard group. These statistics indicate that the new treatment regimen can yield the same therapeutic effects in a shorter timeframe.
Benefits of Accelerated Treatment
The accelerated sessions were designed to be less than 10 minutes each, significantly shortening the duration compared to the traditional 20-minute sessions. This reduction in time not only enhances patient comfort but also alleviates logistical burdens, making access to care more manageable for patients.
Notably, the median time for achieving remission was recorded at 21 days for the accelerated group, whereas it was 28 days for those undergoing standard treatment. This faster recovery period marks a crucial advancement in treatment protocols.
Safety and Acceptance of the New Protocol
Safety considerations remain paramount in any treatment regimen. The accelerated Deep TMS protocol was found to be well tolerated, with no serious adverse events reported among participants. Minor side effects, such as headaches or site discomfort, were consistent with those typically seen in standard TMS treatments.
Innovative Methods Without Complex Technology
Another notable aspect of this study was that it utilized BrainsWay’s efficient H1 Coil without the need for complex neuronavigation equipment, simplifying the procedure for clinics and patients alike.
Dr. Russ Voltin, a board-certified psychiatrist, expressed the importance of this study, stating that for many patients, the ability to attend a clinic less frequently could be a game changer in their treatment journey. He emphasized that innovation in mental health treatment isn't just about new technologies, but also about improving access and delivery of care.
The Future of Deep TMS
BrainsWay’s commitment to advancing the field of neurostimulation is reflected in their ongoing efforts to enhance access to Deep TMS. With multiple clinical trials underway exploring various psychiatric, neurological, and addiction disorders, the company continues to lead the charge in transforming mental health care.
The accelerated protocol still requires further validation through additional analyses and peer reviews. However, preliminary results are indicative of a promising future for patients seeking efficient and effective treatment options.
About BrainsWay
BrainsWay leverages its proprietary technology in Deep Transcranial Magnetic Stimulation (Deep TMS™) to treat a range of mental health disorders. The company proudly holds three FDA-clearances, showcasing its commitment to evidence-based practice and clinical efficacy. BrainsWay focuses on improving quality of life for individuals facing anxiety disorders, OCD, and more. With plans for further research, BrainsWay is dedicated to delivering superior mental health solutions.
For the latest updates on their research, feel free to explore BrainsWay's website at www.brainsway.com.
Frequently Asked Questions
What is the purpose of the Accelerated Deep TMS study?
The study aims to assess the efficacy of an accelerated Deep TMS protocol in treating major depressive disorder compared to standard treatment.
How many patients participated in the trial?
A total of 104 adult patients diagnosed with depression participated in the study.
What improvements were reported from the accelerated group?
The accelerated treatment group showed significant improvements in depressive symptoms, with comparable HDRS score reductions to the standard group.
Were there any safety concerns during the trial?
The accelerated protocol was well tolerated, with no serious adverse events reported, and side effects were consistent with standard TMS treatments.
What does the future hold for the accelerated Deep TMS protocol?
Further analysis and peer-review are required, but preliminary results suggest promising improvements in the accessibility and efficacy of treatment for depression.
